Similarly, proteasome inhibitors MG-115, MG-132, and lactacystin were also shown to promote NF-κB activation in cells through an increase in IKK activation and IκBα degradation, further highlighting how the use of proteasome inhibitors to prevent NF-κB may not necessarily block NF-κB activation in cancer cells [141,167]. This evidence concerns the gene NFKB1 and cancer.